SCHEMBL2941458

SCHEMBL2941458

Nc1cnccc1CN1CC(=O)N(c2ccc(OC(F)(F)F)cc2)C1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R8 Q9NYW2 3/20 0.38
PPARD Q03181 4/20 0.38
PPARA Q07869 4/20 0.38
PPARG P37231 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
ENPP2 Q13822 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 2/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
GCGR P47871 2/20 0.34
NTRK1 P04629 1/20 0.34
TRPV1 Q8NER1 1/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
ROCK2 O75116 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2937749 0.89 PPARD (0.37) TAS2R8PPARDPPARAPPARGL3MBTL1
SCHEMBL2939136 0.88 TAS2R8 (0.38) TAS2R8PPARDPPARAPPARGL3MBTL1
SCHEMBL2940706 0.88 PPARD (0.38) TAS2R8PPARDPPARAPPARGL3MBTL1
SCHEMBL2937375 0.88 PPARD (0.39) TAS2R8PPARDPPARAPPARGL3MBTL1
SCHEMBL2938937 0.88 PPARD (0.43) TAS2R8PPARDPPARAPPARGL3MBTL1
SCHEMBL2934030 0.88 PPARD (0.38) TAS2R8PPARDPPARAPPARGL3MBTL1
SCHEMBL2939386 0.87 SCN9A (0.39) TAS2R8PPARDPPARAPPARGL3MBTL1
SCHEMBL2992187 0.86 ROCK2 (0.40) PPARDPPARAPPARGENPP2GCGR
SCHEMBL2941037 0.86 TAS2R8 (0.41) TAS2R8PPARDPPARAL3MBTL1POLB
SCHEMBL2940696 0.86 PPARD (0.38) TAS2R8PPARDPPARAPPARGL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 TAS2R8 3914/4885PPARD 3189/4885PPARA 4338/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA TAS2R8 4047/4885PPARD 3572/4885PPARA 4692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.